Show simple item record

dc.contributor.authorMc Kee, Gabrielleen
dc.date.accessioned2016-06-23T12:32:27Z
dc.date.available2016-06-23T12:32:27Z
dc.date.issued2015en
dc.date.submitted2015en
dc.identifier.citationMinnock P, Veale DJ, Bresnihan B, FitzGerald O and McKee G., Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis, Clinical Rheumatology, 34, 11, 2015, 1857 - 1865en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/76630
dc.descriptionPUBLISHEDen
dc.description.abstractThe objective of the present study is to determine the factors associated with persistent fatigue in patients with severe rheumatoid arthritis (RA) and good disease response to 6 months of tumour necrosis factor inhibitor therapy. Eligible patients with either persistent (PF) or no fatigue (NF) were compared. Using validated questionnaires and bivariate analysis, this cross-sectional survey explored if clinical characteristics, pain, self-efficacy, sleep and mood/depression differed between groups. Patients with PF (PF; NF) (n = 28; 28) reported significantly more overall pain (11.3 ± 9.4 (0-33); 6.9 ± 8.9 (0-33)), more recent and current pain intensity (41.4 ± 26.6 (0-80) 24.4 ± 26.6 (0-100) and depression (11.8 ± 7.5 (1-35); 8.2 ± 6.6 (0-26)), than the NF group. There was no significant difference between groups in self-efficacy and both groups experienced poor sleep quality (Pittsburgh Sleep Quality Index >5). Despite having good disease response, the PF group had significantly higher rheumatoid factor incidence, disease activity score-28, early morning stiffness duration and lower incidence of ever-failing disease-modifying anti-rheumatic drugs than the NF group. These findings enhance the fatigue literature in patients with RA prescribed tumour necrosis factor (TNF) inhibition therapy, identifying the potentially modifiable factors of pain and depression, previously demonstrated to be strongly associated with fatigue in non-biologic populations. In addition, this study highlights the association between persistent fatigue and an on-going state of low disease activity. This infers that more judicious disease management could minimise the symptom burden of pain and depression and consequentially fatigue.en
dc.format.extent1857en
dc.format.extent1865en
dc.language.isoenen
dc.relation.ispartofseriesClinical Rheumatologyen
dc.relation.ispartofseries34en
dc.relation.ispartofseries11en
dc.rightsYen
dc.subjectDisease outcomeen
dc.subjectFatigueen
dc.subjectPainen
dc.subjectRheumatoid arthritisen
dc.subjectSelf-efficacyen
dc.titleFactors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysisen
dc.typeJournal Articleen
dc.contributor.sponsorHealth Research Board (HRB)en
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/gmckeeen
dc.identifier.rssinternalid112160en
dc.rights.ecaccessrightsopenAccess
dc.relation.doi10.1007/s10067-015-3088-6en
dc.relation.citesCitesen
dc.identifier.rssurihttp://link.springer.com/article/10.1007/s10067-015-3088-6en
dc.identifier.orcid_id0000-0003-0211-5330en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record